Octacosanol in human health

Nutrition

Volumn 19, Issue 2, 2003, Pages 192-195

  Taylor, Johanna C ^a   Rapport, Lisa ^a   Lockwood, G Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALCOHOL; CARNITINE; CHOLESTEROL; CIMETIDINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; INDOMETACIN; LOW DENSITY LIPOPROTEIN; OCTACOSANOL; POLICOSANOL; PRAVASTATIN; THROMBOXANE A2;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BLOOD FLOW; BRAIN ISCHEMIA; CELL MEMBRANE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; EXERCISE; FAMILY HISTORY; HEALTH; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER; LIVER CELL; LIVER FUNCTION; NAUSEA; NONHUMAN; NUTRITION; OBESITY; PLASMA; PRIORITY JOURNAL; RASH; RISK FACTOR; SHORT SURVEY; SMOKING; STOMACH PAIN; STRENGTH; THROMBOCYTE AGGREGATION; TRAINING; VISUAL IMPAIRMENT;

EID: 0037319261     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(02)00869-9     Document Type: Article

References (29)

1. Kato S., Karino K., Hasegawa J., et al. Octacosanol affects lipid metabolism in rats fed on a high fat diet. Br J Nutr. 73:1995;433.
2. Saint-John M., McNaughton L. Octacosanol ingestion and its effects on metabolic responses to submaximal cycle ergometry, reaction time and chest and grip strength. Int Clin Nutr Rev. 6:1986;81.
3. Rang HP, Dale MM, Ritter JM. Pharmacology, 4th ed. London: Churchill Livingstone,1999:830.
4. Castano G., Mas R., Fernandez L., et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol. 14:2000;187.
5. Craig C.R., Stitzel R.E. Modern pharmacology. 907:1994;Little, Brown & Co. 4th ed.
6. Walker R. Hyperlipidaemia. Walker R., Edwards C. Clinical pharmacy and therapeutics. 2nd ed:1999; Churchill Livingstone, Edinburgh.:327.
7. Shimura S., Hasegawa T., Takano S., et al. Studies on the effect of octacosanol on motor endurance in mice. Nutr Rep Int. 36:1987;1029.
8. Arruzazabala M.L., Carbajal D., Mas R., et al. Cholesterol-lowering effects of policosanol in rabbits. Biol Res. 27:1994;205.
9. Hernandez F., Illait J., Mas R., et al. Effect of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res. 51:1992;568.
10. British National Formulary. 124:2001;British Medical Association, London. 41st ed.
11. Bellingham C. Cerivastatin withdrawal the impacts . Pharm J. 267:2001;222.
12. Castano G., Mas R., Arruzazabala M.de L., et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res. 4:1999;105.
13. Fernandez JC, Mas R, Castano G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women. Clin Drug Invest 2001;21:103.
14. Crespo N., Illnait J., Mas R., et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharm Res. 19:1999;117.
15. Pons P., Rodriguez M., Mas R., et al. One-year efficacy and safety of policosanol in patients with type II hypercholesterolaemia. Curr Ther Res. 55:1994;1084.
16. Aneiros E., Mas R., Calderon B., et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolaemia. Curr Ther Res. 56:1995;176.
17. Castano G., Mas R., Nodarse M., et al. One year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolaemia. Curr Ther Res. 56:1995;296.
18. Castano G., Canetti M., Moreira M., et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolaemia a 12-month study . Curr Ther Res. 56:1995;819.
19. Castano G., Tula L., Canetti M., et al. Effects of policosanol in hypertensive patients with type II hypercholesterolaemia. Curr Ther Res. 57:1996;691.
20. Mas R., Castano G., Illnait J., et al. Effects of policosanol in patients with type II hypercholesterolaemia and additional coronary risk factors. Clin Pharmacol Ther. 65:1999;439.
21. Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997:36.
22. 2 . Prostaglandins Leukot Essent Fatty Acids. 49:1993;695.
23. Castano G., Mas R., Roca J., et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology. 50:1999;123.
24. Arruzazabala M.L., Mas R., Molina V., et al. Effects of policosanol on platelet aggreagation in type II hypercholesterolaemic patients. Tissue React. 20:1998;119.
25. Arruzazabala M.L., Carbajal D., Mas R., et al. Effects of policosanol on platelet aggregation in rats. Thromb Res. 69:1993;321.
26. Durden Beltz S., Doering P.L. Efficacy of nutritional supplements used by athletes. Clin Pharm. 12:1993;900.
27. Cockerill D.L., Bucci L.R. Increases in muscle girth and decreases in body fat associated with a nutritional supplement program. Chiropract Sports Med. 1:1987;73.
28. Carbajal D., Molina V., Valdes S., et al. Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Pharmacol. 47:1995;731.
29. Carbajal D., Molina V., Valdes S., et al. Possible cytoprotective mechanism in rats of D-002, an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol. 48:1996;858.